PFE - Pfizer Inc.
36.95 +0.10 (0.27%)
After hours: 6:48PM EDT
| Previous Close | 36.68 |
| Open | 36.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 36.75 - 37.10 |
| 52 Week Range | 31.67 - 39.43 |
| Volume | 19,360,179 |
| Avg. Volume | 25,241,191 |
| Market Cap | 219.206B |
| Beta | 0.95 |
| PE Ratio (TTM) | 10.48 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.70%) |
| Ex-Dividend Date | 2018-02-01 |
| 1y Target Est | N/A |
Yahoo Finance Video•2 days agoNEWS BITES: Police look for motive in deadly Toronto van attack, President George H.W. Bush hospitalized, Prince's family suing hospital that treated him
Here’s a quick wrap up of other headlines making news today.
Yahoo Finance Video•2 days agoHere’s why Amazon won’t go into pharma: hedge fund billionaire
Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.
- Reuters•10 hours ago
Bristol-Myers raises 2018 forecast, some sales disappoint
Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down ...
- Zacks•13 hours ago
Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.
- Market Realist•13 hours ago
Analyst Recommendations for Biogen in April
In March, Biogen (BIIB) entered into an agreement with Pfizer (PFE) to acquire Pfizer’s investigational drug PF-04958242, a Phase 2b–ready AMPA (α-amino-3-hydroxy-5 methyl-4-isoxazolepropionic acid) receptor potentiator for cognitive impairment related to schizophrenia. Biogen will make an upfront payment of $75 million to Pfizer and up to $515 million as additional development and commercialization milestone payments. Pfizer is also subject to receive tiered royalty payments from Biogen.
- Market Realist•13 hours ago
Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth
In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.
- Motley Fool•16 hours ago
3 Top Dividend Stocks With Yields Over 3%
A 10-year U.S. Treasury note may yield 3% right now, but these Fools think these stocks are a better investment.
- Market Realist•yesterday
Sanofi’s 1Q18: Revenue Expected to Fall
As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.
- Market Realist•yesterday
GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.
- Market Realist•yesterday
Analysts’ Estimates for Sanofi’s 1Q18 Earnings
Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.
- Market Realist•2 days ago
Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.
- Market Realist•2 days ago
How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.
- Market Realist•2 days ago
What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.
- Zacks•2 days ago
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
- Market Realist•2 days ago
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.
Market Realist•2 days agoGilead Sciences’ Inflammation Research Is Seeing Rapid Progress
Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.
- Market Realist•2 days ago
Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen
- MarketWatch•2 days ago
Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says
In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.
- Market Realist•2 days ago
How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
- Market Realist•3 days ago
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.
- Market Realist•3 days ago
Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.
- Motley Fool•3 days ago
Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
It's a lot easier to be patient once those quarterly payments start adding up.
- Motley Fool•3 days ago
Don't Get Greedy With Novavax, Inc. Stock
Novavax's abysmal track record should be a huge red flag for potential shareholders.
- Market Realist•3 days ago
Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
